Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease

Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a major health issue worldwide, frequently associated with obesity and type 2 diabetes. Steatosis is the initial stage of the disease, which is characterized by lipid accumulation in hepatocytes, which can progress to non-alcoholic steatohepatitis (NASH)...

Full description

Bibliographic Details
Main Authors:	Anne Fougerat, Alexandra Montagner, Nicolas Loiseau, Hervé Guillou, Walter Wahli
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	Cells
Subjects:	peroxisome proliferator-activated receptors (PPARs) synthetic agonists non-alcoholic fatty liver disease (NAFLD) non-alcoholic steatohepatitis (NASH) fibrosis
Online Access:	https://www.mdpi.com/2073-4409/9/7/1638

Similar Items

Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease
by: Fougerat, Anne, et al.
Published: (2020)

Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
by: Clémence Rives, et al.
Published: (2020-12-01)

Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome
by: Tan, Chek Kun, et al.
Published: (2017)

The metabolite, alpha-ketoglutarate inhibits non-alcoholic fatty liver disease progression by targeting lipid metabolism
by: Katsuya Nagaoka, et al.
Published: (2020-06-01)

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
by: Abdul Haseeb Hasan, et al.
Published: (2025-01-01)

A case of metabolic syndrome, positive antinuclear antibodies and cirrhosis.
by: Alessandro Grasso
Published: (2007-09-01)

Preventative and Therapeutic Effects of Astaxanthin on NAFLD
by: Nor Hafiza Sayuti, et al.
Published: (2023-08-01)

Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
by: Deniz Tümen, et al.
Published: (2022-12-01)

The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease
by: Sun Xin, et al.
Published: (2017-03-01)

Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients
by: Yan Huang, et al.
Published: (2022-01-01)

Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease
by: HAO Dandan, ZHANG Lei, BAI Chunying
Published: (2023-08-01)

Loss of hepatic VMP1 trapped VLDL in the bilayer of endoplasmic reticulum membrane
by: Hong-Min Ni, et al.
Published: (2023-06-01)

Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD
by: Victoria Svop Jensen, et al.
Published: (2021-02-01)

NAFLD: Challenges and opportunities to address the public health problem in Latin America
by: Juan Pablo Arab, et al.
Published: (2021-09-01)

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease
by: Chong Song, et al.
Published: (2023-03-01)

Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study
by: Syed Mushfiq, et al.
Published: (2025-01-01)

Effect of High-intensity Intermittent Swimming Training on peroxisome proliferator-activated receptors-αand Liver Enzymes in Non-alcoholic Steatohepatitis Male Rats
by: Alireza Jowhari, et al.
Published: (2023-01-01)

EPIDEMIOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE IN NOVOSIBIRSK (SIBERIAN FEDERAL DISTRICT): REGIONAL DATA OF OPEN MULTICENTER PROSPECTIVE STUDY DIREG 2
by: V. V. Tsukanov, et al.
Published: (2016-09-01)

PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY)
by: D. Kh. Kalimullina, et al.
Published: (2017-03-01)

Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Nelson Kei, et al.
Published: (2023-09-01)

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
by: Christoph Roderburg, et al.
Published: (2023-04-01)

Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages
by: Charles Drummer, et al.
Published: (2023-01-01)

Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis
by: Nicha Wongjarupong, et al.
Published: (2017-12-01)

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
by: Stephen Caldwell
Published: (2017-06-01)

The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia
by: Iason Psilopatis, et al.
Published: (2023-02-01)

Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) <it>in vitro</it>
by: Dionisi Mauro, et al.
Published: (2012-05-01)

The effect of probiotic supplementation on non-alcoholic fatty liver disease (NAFLD) fibrosis score in patients attending a tertiary hospital clinic in Cairo, Egypt
by: Alaa Ahmed Abd El Hamid, et al.
Published: (2024-10-01)

Genistein and Sex Hormone Supplementation Modulated Hepatic PPARα, δ, and γ Subtypes and STAT1 Expressions in a NASH Rat Model with Bilateral Orchidectomy
by: Fatist Okrit, et al.
Published: (2024-02-01)

Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis
by: Nancy Magee, et al.
Published: (2022-12-01)

NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL
by: D. V. Blinov
Published: (2015-12-01)

Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease: a review
by: Yalan Deng, et al.
Published: (2024-09-01)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
by: Gregory Habig, et al.
Published: (2021-04-01)

Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
by: Ye Eun Cho, et al.
Published: (2023-03-01)

Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
by: Sukrit Kanchanasurakit, et al.
Published: (2022-05-01)

Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
by: Yang Xiao, et al.
Published: (2021-08-01)

NASH and cryptogenic cirrhosis: A histological analysis†† Financial Support/Grants: This research supported in part by the Intramural Research Program of the NIH, National Cancer Institute.
by: Stephen H. Caldwell, et al.
Published: (2009-10-01)

Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis
by: Adnan Said, et al.
Published: (2017-07-01)

PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGL
by: Hagen Roland Witzel, et al.
Published: (2022-12-01)

Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)
by: Yuan-Ye Qiu, et al.
Published: (2023-06-01)

Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growth
by: Fereshteh Asgharzadeh, et al.
Published: (2024-09-01)